Table 1 Patient demographics at baseline
From: First-in-human phase Ia study of the PI3Kα inhibitor CYH33 in patients with solid tumors
Characteristic | DL1–4 CYH33, 1–20 mg QD n = 10 | DL5 CYH33, 30 mg QD n = 12 | DL6 CYH33, 40 mg QD n = 24 | All patients CYH33, 1–60 mg QD n = 51 |
|---|---|---|---|---|
Age (years) median (range) | 55.5 (47, 67) | 54.5 (34, 70) | 49.0 (26, 73) | 54.0 (26, 73) |
Sex (male/female) | 6/4 | 4/8 | 9/15 | 22/29 |
ECOG status, n (%) | ||||
0 | 4 (40.0) | 3 (25.0) | 10 (41.7) | 18 (35.3) |
1 | 6 (60.0) | 9 (75.0) | 14 (58.3) | 33 (64.7) |
Number of prior systemic regimens, n (%) | ||||
1 | 2 (20.0) | 7 (58.3) | 10 (41.7) | 19 (37.3) |
2 | 2 (20.0) | 2 (16.7) | 6 (25.0) | 12 (23.5) |
3 | 2 (20.0) | 0 | 3 (12.5) | 8 (15.7) |
≥4 | 4 (40.0) | 3 (25.0) | 5 (20.8) | 12 (23.5) |
Number of metastatic sites, n (%) | ||||
1 | 0 | 1 (8.3) | 7 (29.2) | 9 (17.6) |
2 | 4 (40.0) | 4 (33.3) | 7 (29.2) | 16 (31.4) |
≥3 | 6 (60.0) | 7 (58.3) | 10 (41.7) | 26 (51.0) |
Status of PIK3CA, n (%) | ||||
Mutant | 4 (40.0) | 12 (100.0) | 17 (70.8) | 36* (70.6) |
Wild type | 0 | 0 | 0 | 0 |
Unknown | 6 (60.0) | 0 | 7 (29.2) | 15 (29.4) |
